The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and alzheimer-like pathology in an interventional study with aged tau transgenic mice

Journal of Neuroscience

Volumn 32, Issue 11, 2012, Pages 3601-3611

  Zhang, Bin ^a   Carroll, Jenna ^a   Trojanowski, John Q ^a   Yao, Yuemang ^a   Iba, Michiyo ^a   Potuzak, Justin S ^b   Hogan, Anne Marie L ^b   Xie, Sharon X ^a   Ballatore, Carlo ^a,b   Smith III, Amos B ^a   Lee, Virginia M Y ^a   Brunden, Kurt R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPOTHILONE D; NEURON SPECIFIC NUCLEAR PROTEIN; SYNAPTOPHYSIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BLOOD CELL COUNT; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPAL CA3 REGION; IMMUNOHISTOCHEMISTRY; INTERVENTION STUDY; MALE; MAZE TEST; MICROTUBULE; MOUSE; NERVE FIBER DEGENERATION; NERVE FIBER TRANSPORT; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TAUOPATHY; TRANSGENIC MOUSE; TRANSMISSION ELECTRON MICROSCOPY;

AGING; ALZHEIMER DISEASE; ANIMALS; AXONS; COGNITION DISORDERS; EPOTHILONES; HUMANS; MALE; MICE; MICE, TRANSGENIC; MICROTUBULES; NEUROTOXICITY SYNDROMES; TAU PROTEINS; TAUOPATHIES; TUBULIN MODULATORS;

EID: 84863230105     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4922-11.2012     Document Type: Article

References (63)

1. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimers disease. Neurology 42:631-639.
2. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8:663-672.
3. Bedard PL, Di Leo A, Piccart-Gebhart MJ (2010) Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 7:22-36.
4. Beer TM, Higano CS, Saleh M, Dreicer R, Hudes G, Picus J, Rarick M, Fehrenbacher L, Hannah AL (2007) Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 25:565-570.
5. Black MM, Baas PW, Humphries S (1989) Dynamics of alpha-tubulin deacetylation in intact neurons. J Neurosci 9:358-368.
6. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM (1995) Epothilones, a new class of microtubulestabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333.
7. Brady ST, Witt AS, Kirkpatrick LL, de Waegh SM, Readhead C, Tu PH, Lee VM (1999) Formation of compact myelin is required for maturation of the axonal cytoskeleton. J Neurosci 19:7278-7288.
8. Bramblett GT, Trojanowski JQ, Lee VM (1992) Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent-tau and accumulation of abnormal tauisoforms (A68 proteins). Lab Invest 66:212-222.
9. Brunden KR, Trojanowski JQ, Lee VM (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8:783-793.
10. Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM, Iba M, James MJ, Xie SX, Ballatore C, Smith AB 3rd, Lee VM, Trojanowski JQ (2010) Epothilone D improves microtubule density, axonal integrity and cognition in a transgenic mouse model of tauopathy. J Neurosci 30:13861-13866.
11. Brunden KR, Yao Y, Potuzak JS, Ferrer NI, Ballatore C, James MJ, Hogan AM, Trojanowski JQ, Smith AB 3rd, Lee VM (2011) The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. Pharmacol Res 63:341-351.
12. Carroll JC, Rosario ER, Chang L, Stanczyk FZ, Oddo S, LaFerla FM, Pike CJ (2007) Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci 27:13357-13365.
13. Cash AD, Aliev G, Siedlak SL, Nunomura A, Fujioka H, Zhu X, Raina AK, Vinters HV, Tabaton M, Johnson AB, Paula-Barbosa M, Avíla J, Jones PK, Castellani RJ, Smith MA, Perry G (2003) Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. AmJ Pathol 162:1623-1627.
14. Cheng KL, Bradley T, Budman DR (2008) Novel microtubule-targeting agents-the epothilones. Biologics 2:789-811.
15. Cleveland DW, Connolly JA, Kalnins VI, Spiegelman BM, Kirschner MW (1977a) Physical properties and cellular localization of tau, a microtubuleassociated protein which induces assembly of purified tubulin. J Cell Biol 75:A283.
16. Cleveland DW, Hwo SY, Kirschner MW (1977b) Physical and chemical properties of purified tau factor and role of tau in microtubule assembly. J Mol Biol 116:227-247.
17. Cortes J, Baselga J (2007) Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 12:271-280.
18. Crowe A, Huang W, Ballatore C, Johnson RL, Hogan AM, Huang R, Wichterman J, McCoy J, Huryn D, Auld DS, Smith AB 3rd, Inglese J, Trojanowski JQ, Austin CP, Brunden KR, Lee VM (2009) The identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48:7732-7745.
19. Dixit R, Ross JL, Goldman YE, Holzbaur EL (2008) Differential regulation of dynein and kinesin motor proteins by tau. Science 319:1086-1089.
20. Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW, Wang L, Züchner S, Konidari I, Wang G, Singer C, Nahab F, Scott B, Stajich JM, Pericak-Vance M, Haines J, Vance JM, Martin ER (2010) Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 74:97-109.
21. Falzone TL, Stokin GB, Lillo C, Rodrigues EM, Westerman EL, Williams DS, Goldstein LS (2009) Axonal stress kinase activation and tau misbehavior induced by kinesin-1 transport defects. J Neurosci 29:5758-5767.
22. Falzone TL, Gunawardena S, McCleary D, Reis GF, Goldstein LS (2010) Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies. Hum Mol Genet 19:4399-4408.
23. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhänel M, Spruss T, Bernhardt G, Graeff C, Färber L, Gschaidmeier H, Buschauer A, Fricker G (2002) Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110:1309-1318.
24. Goedert M, Jakes R (2005) Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta 1739:240-250.
25. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA (1989) Cloning and sequencing of the cdna-encoding an isoform of microtubule-associated protein tau containing 4 tandem repeats: differential expression of tau protein messenger-rnas in human-brain. EMBO J 8:393-399.
26. Goedert M, Jakes R, Vanmechelen E (1995) Monoclonal-antibody At8 recognizes tau-protein phosphorylated at both serine-202 and threonine-205. Neurosci Lett 189:167-169.
27. Gómez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41:17-24.
28. Gravitz L (2011) A tangled web of targets. Nature 475:S9-S11.
29. Harrison FE, Hosseini AH, McDonald MP (2009) Endogenous anxiety and stress responses in water maze and Barnes maze spatial memory tasks. Behav Brain Res 198:247-251.
30. Hempen B, Brion JP (1996) Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J Neuropathol Exp Neurol 55:964-972.
31. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, Geschwind DH, Bird TD, McKeel D, Goate A, Morris JC, Wilhelmsen KC, Schellenberg GD, Trojanowski JQ, Lee VM (1998) Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282:1914-1917.
32. Hughes RN (2004) The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci Biobehav Rev 28:497-505.
33. Hunt JT (2009) Discovery of ixabepilone. Mol Cancer Ther 8:275-281.
34. Hurtado DE, Molina-Porcel L, Iba M, Aboagye AK, Paul SM, Trojanowski JQ, Lee VM (2010) A beta accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol 177:1977-1988.
35. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakravarty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, et al. (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:702-705.
36. Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ, Lee VM (1999) Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24:751-762.
37. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9:119-128.
38. Jicha GA, Bowser R, Kazam IG, Davies P (1997) Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res 48:128-132.
39. Kalaitzakis ME, Pearce RK (2009) The morbid anatomy of dementia in Parkinson's disease. Acta Neuropathol 118:587-598.
40. Kar S, Fan J, Smith MJ, Goedert M, Amos LA (2003) Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J 22:70-77.
41. King DL, Arendash GW (2002) Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol Behav 75:627-642.
42. Kirkpatrick LL, Witt AS, Payne HR, Shine HD, Brady ST (2001) Changes in microtubule stability and density in myelin-deficient shiverer mouse CNS axons. J Neurosci 21:2288-2297.
43. Laferrière NB, MacRae TH, Brown DL (1997) Tubulin synthesis and assembly in differentiating neurons. Biochem Cell Biol 75:103-117.
44. Laird NM, Ware JH (1982) Random-effects models for longitudinal data. Biometrics 38:963-974.
45. Lee CB, Wu Z, Zhang F, Chappell MD, Stachel SJ, Chou TC, Guan Y, Danishefsky SJ (2001a) Insights into long-range structural effects on the stereochemistry of aldol condensations: a practical total synthesis of desoxyepothilone F. J Am Chem Soc 123:5249-5259.
46. Lee VM, Daughenbaugh R, Trojanowski JQ (1994) Microtubule stabilizing drugs for the treatment of Alzheimers-disease. Neurobiol Aging 15:S87-S89.
47. Lee VM, Goedert M, Trojanowski JQ (2001b) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121-1159.
48. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, LaFerla FM, Gozes I, Aisen PS (2007) Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 31:165-170.
49. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS (2008) A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 325:146-153.
50. Patil SS, Sunyer B, Höger H, Lubec G (2009) Evaluation of spatial memory of C57BL/6J and CD1 mice in the Barnes maze, the multiple T-maze and in the Morris water maze. Behav Brain Res 198:58-68.
51. Pitcher GM, Ritchie J, Henry JL (1999) Paw withdrawal threshold in the von Frey hair test is influenced by the surface on which the rat stands. J Neurosci Methods 87:185-193.
52. Rivkin A, Yoshimura F, Gabarda AE, Cho YS, Chou TC, Dong H, Danishefsky SJ (2004) Discovery of (E)-9,10-dehydroepothilones through chemical synthesis: on the emergence of 26-trifluoro-(E)-9,10-dehydro-12,13-desoxyepothilone B as a promising anticancer drug candidate. J Am Chem Soc 126:10913-10922.
53. Rosario ER, Carroll JC, Oddo S, LaFerla FM, Pike CJ (2006) Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. J Neurosci 26:13384-13389.
54. Samsonov A, Yu JZ, Rasenick M, Popov SV (2004) Tau interaction with microtubules in vivo. J Cell Sci 117:6129-6141.
55. Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Krüger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41:1308-1312.
56. Smith SB, Crager SE, Mogil JS (2004) Paclitaxel-induced neuropathic hypersensitivity in mice: responses in 10 inbred mouse strains. Life Sci 74:2593-2604.
57. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156:1051-1063.
58. Tlhyama T, Lee VM, Trojanowski JQ (1993) Coexpression of lowmolecular-weight neurofilament protein and glial fibrillary acidic protein in established human glioma cell-lines. Am J Pathol 142:883-892.
59. Vershinin M, Carter BC, Razafsky DS, King SJ, Gross SP (2007) Multiplemotor based transport and its regulation by tau. Proc Natl Acad Sci U S A 104:87-92.
60. Wilcock GK, Esiri MM (1982) Plaques, tangles and dementia-a quantitative study. J Neurol Sci 56:343-356.
61. Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI, Mandelkow EM, Diamond MI, Lee VM, Holtzman DM (2011) In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci 31:13110-13117.
62. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53:337-351.
63. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, Li C, Toleikis PM, Lee VM, Trojanowski JQ (2005) Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A 102:227-231